GLP-1 telehealth brands and websites named in FDA warning letters
Which GLP-1 telehealth websites has FDA named in warning letters?
As of Nov 15, 2026, all 111 FDA GLP-1 warning letters to telehealth companies in this index name the company’s website, and 141 websites appear across all 155 letters, including tryeden.com (Eden Health International Inc. dba Eden, Jun 8, 2026), ivimhealth.com (Ivim Services LLC dba Ivim, Feb 20, 2026) and hims.com (Hims & Hers Health, Inc. dba Hims, Sep 9, 2025). The table matches each website to the legal name FDA addressed.
Website addresses are copied from the letter text on fda.gov. A website missing here has not been named in a GLP-1 warning letter in this index; that is not a finding about it.
| Letter | |||||
|---|---|---|---|---|---|
| 24hrdoc.com | 24HrDoc, Inc. dba 24HrDoc | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.24hrdoc.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| 24hreup.biz | www.24hreup.biz | Online seller | Apr 23, 2025 | Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet addresses www.24hreup.biz and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| 24hreup.com | www.24hreup.biz | Online seller | Apr 23, 2025 | Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet The letter’s words: “We advise you to review your websites (including www.24hreup.com which forwards to www.24hreup.biz), product labels, and other labeling and promotional materials to ensure that you are not misleadingly …” | fda.gov |
| alanmeds.com | Alan Health Technologies Inc. dba Alan | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.alanmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| all-american-wellness.com | All American Wellness | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://all-american-wellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| altrutelehealth.com | Altru Telehealth, LLC dba Altru Telehealth | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Altru Telehealth’s website, https://altrutelehealth.com, FDA Establishment Identifier (FEI) 3044020130, in March 2026.” | fda.gov |
| altrx.com | Trinity HealthCare Supply, LLC dba altRx | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of altRx’s website, https://www.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026.” | fda.gov |
| amazing-meds.com | Amazing Meds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://amazing-meds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.” | fda.gov |
| anumed-intl.com | AnuMed International, LLC | Not stated | Aug 20, 2024 | Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded The letter’s words: “FDA also reviewed your website at the Internet address https://www.anumed-intl.com/ in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” …” | fda.gov |
| asn-labs.com | ASN-LABS | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://asn-labs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.” | fda.gov |
| bluefitmd.com | BluefitMD | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.bluefitmd.com/, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| bodygoodstudio.com | Body Good Studio | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.bodygoodstudio.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| buynetmeds.com | www.buynetmeds.com | Online seller | Jun 12, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.buynetmeds.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| canadamedstop.com | Canada Med Stop | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.canadamedstop.com in August 2025 and has observed that your website offers compounded semaglutide drug products.” | fda.gov |
| cheapmedicineshop.com | Cheap Medicine Shop/www.cheapmedicineshop.com | Internet pharmacy | Sep 24, 2026 | Unapproved New Drugs/Misbranded (Internet Pharmacy) The letter’s words: “Food and Drug Administration (FDA) review of your website www.cheapmedicineshop.com.” | fda.gov |
| cheaptrustedpharmacy.com | cheaptrustedpharmacy.com | Online seller | Jul 29, 2025 | Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.cheaptrustedpharmacy.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| clovermeds.com | Clover Meds LLC dba Clover Meds | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Clover Meds’ website, https://clovermeds.com, FDA Establishment Identifier (FEI) 3044175705, in March 2026.” | fda.gov |
| coretrustlabs.com | EA WORKS Limited Liability Company dba Trust Labs | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://coretrustlabs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide.” | fda.gov |
| cosmomedspa.com | Cosmo Medical Spa dba Cosmo Med Spa | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://cosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| dashpct.com | www.dashpct.com | Online seller | Apr 24, 2024 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.dashpct.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| deluxeivaesthetics.com | Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://deluxeivaesthetics.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| dhmedicalcenter.com | D&H Medical Services | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of D&H Medical Services’ website, https://www.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026.” | fda.gov |
| directmeds.com | directmeds.com, Inc. dba DirectMeds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://directmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| drgatergetsresults.com | Dr. Gater’s Weight Loss & Wellness | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://drgatergetsresults.com in September 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| drjennpb.com | MedClub by Dr. Jenn | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://drjennpb.com in June 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.” | fda.gov |
| drmedhealth.com | Public Health Solution LLC dba DrMedHealth | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of DrMedHealth’s website, https://drmedhealth.com, FDA Establishment Identifier (FEI) 3044020737, in March 2026.” | fda.gov |
| edrugstore.com | eDrugstore | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.edrugstore.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.” | fda.gov |
| elevatedhealth.com | Elevate Your Wellness LLC, dba Elevated | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://elevatedhealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| eliterapidfatloss.com | Elite Health Center | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://eliterapidfatloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| erasingage.com | Expert Aesthetics | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://erasingage.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| evolifewellness.com | EvoLife Wellness | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://evolifewellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| fancymeds.com | Fancy Meds, LLC dba Fancy Meds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fancymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| fifty410.com | Aspen Aesthetics dba Fifty 410 | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fifty410.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| fitish.com | FITISH | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of FITISH’s website, https://fitish.com, FDA Establishment Identifier (FEI) 3044018836, in March 2026.” | fda.gov |
| fitrxapp.com | FitRX, LLC dba FitRx | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fitrxapp.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| forhers.com | Hims & Hers Health, Inc. dba Hers | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.forhers.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| fwd.care | FWD Care, Inc. dba FWD | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fwd.care in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| genlabmeds.com | GenLabMeds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://genlabmeds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide, and tirzepatide.” | fda.gov |
| getamrx.com | FitRX, LLC dba AM RX | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of AM RX’s website, https://getamrx.com, FDA Establishment Identifier (FEI) 3044021238, in March 2026.” | fda.gov |
| getcurex.com | Curex | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://getcurex.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| getfitmedical.com | Get.Fit.Medical, LLC dba Get.Fit.Medical | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, …” | fda.gov |
| getzealthy.com | FitRX, LLC dba Zealthy | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.getzealthy.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| getzeuss.com | Zeuss LLC dba Zeuss | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://getzeuss.com/, in December 2025, and has observed that your website offers compounded drug products, including tirzepatide drug products.” | fda.gov |
| glp1solution.store | GLP-1 Solution | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide.” | fda.gov |
| gobioverse.com | Bioverse, Inc. dba Bioverse | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.gobioverse.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| goodgirlrx.com | Good Girl LLC dba GoodGirlRX | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://goodgirlrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| gorillahealing.com | www.gorillahealing.com | Not stated | Oct 2, 2023 | Finished Pharmaceuticals/Unapproved New Drug/Misbranded The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.gorillahealing.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| grampeptides.com | Gram Peptides | Online seller | Mar 31, 2026 | Unapproved New Drugs Sold Over the Internet The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://grampeptides.com from January to March 2026.” | fda.gov |
| harpermeds.com | Nexus Health Solutions LLC dba Harper Meds | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Harper Meds’ website, https://www.harpermeds.com, FDA Establishment Identifier (FEI) 3044020867, in March 2026.” | fda.gov |
| healberry.com | HealBerry | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healberry.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| healthon.com | Healthon Inc. dba Healthon | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthon.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| healthyliving.clinic | Healthy Living Clinic | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthyliving.clinic in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| healthymale.com | Healthy Male | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthymale.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.” | fda.gov |
| helixchem.com | Synthetix Inc. DBA Helix Chemical Supply | Not stated | Feb 7, 2024 | Unapproved New Drugs/Misbranded The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States.” | fda.gov |
| hims.com | Hims & Hers Health, Inc. dba Hims | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.hims.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| hydramed.com | HydraMed IV LLC dba HydraMed | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of HydraMed’s website, https://hydramed.com, FDA Establishment Identifier (FEI) 3044021141, in March 2026.” | fda.gov |
| inspire.clinic | inspire.clinic | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 inspire.clinic: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet …” | fda.gov |
| intimaterose.com | Intimate Rose | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.intimaterose.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| invigoratemedspa.com | Invigorate Med Spa | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://invigoratemedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| ivimhealth.com | Ivim Services LLC dba Ivim | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.ivimhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| ivisitdoc.com | iVisitDoc, Inc. dba iVisitDoc | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://ivisitdoc.com in August 2025 and has observed that your website offers various compounded semaglutide drug products.1 As described below, your claims …” | fda.gov |
| joiandblokes.com | Joi and Blokes dba Joi + Blokes | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Joi + Blokes’ website, https://joiandblokes.com, FDA Establishment Identifier (FEI) 3044021205, in March 2026.” | fda.gov |
| joinbelle.com | Belle Health LLC dba Belle | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbelle.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| joinbliv.com | Bliv Wellness LLC dba Bliv | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbliv.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| joinezra.com | Ezra Holdco LLC dba Ezra | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Ezra’s website, https://joinezra.com, FDA Establishment Identifier (FEI) 3045074898, in May 2026.” | fda.gov |
| joinjosie.com | Join Josie | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinjosie.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| joinlevity.com | Levity Inc. dba Levity | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinlevity.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and liraglutide drug products.” | fda.gov |
| joinsprouthealth.com | Sprout Health Partners LLC dba Sprout Health | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinsprouthealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| joinweightcare.com | Weightless Medical LLC dba WeightCare | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinweightcare.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| julymd.com | JulyMD | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://julymd.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| kinmeds.com | Kin Meds | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://kinmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| leandreamsweightloss.com | Lean Dreams LLC dba LeanDreams | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.leandreamsweightloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| lovelymeds.com | Lovely Meds, Inc. dba Lovely Meds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.lovelymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| lumimeds.com | Lumimeds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://lumimeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| maneandsteel.com | Mane & Steel, LLC. dba Mane & Steel | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maneandsteel.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| master-pharmaceuticals.com | Master Pharmaceuticals Group | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.master-pharmaceuticals.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| maximustribe.com | Maximus Health, Inc. dba Maximus | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Maximus’ website, https://www.maximustribe.com, FDA Establishment Identifier (FEI) 3032037948, in May 2026.” | fda.gov |
| maxlife.com | MaxLife Technologies Inc. dba Maxlife | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| medicaweightloss.com | Medica Weight Loss | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Medica Weight Loss’ website, https://medicaweightloss.com, FDA Establishment Identifier (FEI) 3044019522, in March 2026.” | fda.gov |
| medvi.io | MEDVi, LLC dba MEDVi | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://medvi.io, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| mintmed.com | Glow Medispa, LLC dba Mint Med | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Mint Med’s website, https://mintmed.com, FDA Establishment Identifier (FEI) 3044896930, in May 2026.” | fda.gov |
| momentumhealth360.com | Momentum Health 360 dba Momentum Health | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Momentum Health’s website, https://momentumhealth360.com, FDA Establishment Identifier (FEI) 3043997131, in March 2026.” | fda.gov |
| motionpharmacy.com | motionpharmacy.com | Not stated | Sep 10, 2025 | Unapproved New Drug/Misbranded The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.motionpharmacy.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| myamphealth.com | Dripgym Mobile Parent, LLC dba Amp Health | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://myamphealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug …” | fda.gov |
| mystarthealth.com | Matthew Stern, CEO MyStart Health LLC. | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide.” | fda.gov |
| nativemed.net | NativeMed LLC dba NativeMed | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of NativeMed’s website, https://www.nativemed.net, FDA Establishment Identifier (FEI) 3044024130, in March 2026.” | fda.gov |
| newmanclinic.com | Newman Clinic, PLLC dba Newman Clinic | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.newmanclinic.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| newself.com | NewSelf Limited dba NewSelf | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.newself.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| nexlife.us | Nexlife Inc. dba Nexlife | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Nexlife’s website, https://nexlife.us, FDA Establishment Identifier (FEI) 3044820290, in March 2026.” | fda.gov |
| nomida.biz | Nomida.biz | Not stated | Sep 12, 2024 | Unapproved New Drugs/Misbranded The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.nomida.biz and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| novarx.co | Nova Vascular LLC dba NOVARX | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of NOVARX’s website, https://novarx.co, FDA Establishment Identifier (FEI) 3044022416, in March 2026.” | fda.gov |
| nusciencepeptides.com | NuScience Peptides LLC | Not stated | Aug 24, 2026 | Unapproved New Drugs/Misbranded The letter’s words: “FDA Review Violations were identified and documented during a review of your website nusciencepeptides.com in July 2026.” | fda.gov |
| nuvolifehealth.com | Nuvo Life Health Inc. dba Nuvo Life Health | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://nuvolifehealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| onlinegenericmedicine.com | Online Generic Medicine/www.onlinegenericmedicine.com | Internet pharmacy | Sep 23, 2026 | Unapproved New Drug/Misbranded (Internet Pharmacy) The letter’s words: “Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com.” | fda.gov |
| orderlymeds.com | OrderlyMeds LLC dba OrderlyMeds | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of OrderlyMeds’ website, https://orderlymeds.com, FDA Establishment Identifier (FEI) 3044027176, in March 2026.” | fda.gov |
| ozempen.com | Ozempen.com | Online seller | Jun 24, 2024 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.ozempen.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| peacefulmeds.com | www.peacefulmeds.com | Online seller | May 5, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.peacefulmeds.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| peakscurative.com | Peaks Curative, LLC dba Peaks | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://peakscurative.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.” | fda.gov |
| pekcuralabs.com | PekCura Labs | Online seller | Mar 31, 2026 | Unapproved New Drugs Sold Over the Internet The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://pekcuralabs.com/ in January 2026.” | fda.gov |
| pharmazee.co | PharmaZee | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://pharmazee.co, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| pinkponypeptides.com | Lovega LLC dba Pink Pony Peptides | Online seller | Mar 31, 2026 | Unapproved New Drugs Sold Over the Internet The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://pinkponypeptides.com/ in December 2025.” | fda.gov |
| pppepz.com | Peak Performance Peptides | Not stated | Aug 24, 2026 | Unapproved New Drugs/Misbranded The letter’s words: “FDA Review Violations were identified and documented during a review of your website pppepz.com in July 2026.” | fda.gov |
| premiumhealth.us | Premium Health Management Inc. dba Premium Health | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://premiumhealth.us, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| prime-sciences.com | Prime Sciences | Online seller | Mar 31, 2026 | Unapproved New Drugs Sold Over the Internet The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://prime-sciences.com/ from January to March 2026.” | fda.gov |
| primepeptides.co | Prime Vitality, Inc. dba Prime Peptides | Not stated | Dec 10, 2024 | Unapproved New Drugs/Misbranded The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://primepeptides.co in October 2024 and has observed that your website offers various products as “peptides” including, “Semaglutide” and “Retatrutide.” We …” | fda.gov |
| readymednow.com | Ready Med | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Ready Med’s website, https://readymednow.com, FDA Establishment Identifier (FEI) 3044868483, in May 2026.” | fda.gov |
| refills.com | Refills Health, LLC dba Refills Health | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.refills.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.” | fda.gov |
| remedymeds.com | Remedy Meds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://remedymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| resetiv.com | Reset IV, LLC dba Reset IV | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://resetiv.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| roenrx.com | Roen Health, Inc. dba RoenRx | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of RoenRx’s website, https://roenrx.com, FDA Establishment Identifier (FEI) 3044022969, in March 2026.” | fda.gov |
| ronanrx.com | RonanRx, Inc. dba RonanRx | Telehealth | Oct 30, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of RonanRx’s website, https://ronanrx.com and associated social media platforms, FDA Establishment Identifier (FEI) 3048890334, in September 2026.” | fda.gov |
| royal-peptides.com | Royal Peptides LLC | Not stated | Aug 24, 2026 | Unapproved New Drugs/Misbranded The letter’s words: “FDA Review Violations were identified and documented during a review of your website royal-peptides.com in July 2026.” | fda.gov |
| rxmadesimple.com | SimpleRx | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://rxmadesimple.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| sema.bio | SemaBio | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://sema.bio in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| semaspace.com | www.semaspace.com | Not stated | Oct 2, 2023 | Finished Pharmaceuticals/Unapproved New Drug/Misbranded The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.semaspace.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| skinnyrx.com | Lean Rx, Inc. dba SkinnyRx | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://skinnyrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| skool.com | Mile High Compounds LLC | Online seller | Mar 31, 2026 | Unapproved New Drugs Sold Over the Internet The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://milehighcompounds.is, which links to your community forum www.skool.com/milehighcompoundsofficial/, from January to March 2026.” | fda.gov |
| slendid.com | Slendid | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://slendid.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| struthealth.com | Strut Health, LLC dba Strut | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.struthealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| summitpeptides.shop | Summit Research Peptides | Not stated | Dec 10, 2024 | Unapproved New Drugs/Misbranded The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://summitpeptides.shop in October 2024 and has observed that your website offers “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” …” | fda.gov |
| texpeptide.com | TXP Innovations LLC dba Tex Peptides | Not stated | Aug 24, 2026 | Unapproved New Drugs/Misbranded The letter’s words: “FDA Review Violations were identified and documented during a review of your website texpeptide.com in July 2026.” | fda.gov |
| thehcginstitute.com | The HCG Institute | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://thehcginstitute.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| thelyferx.com | Lyfe Rx | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://thelyferx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| thrivelab.com | Thrivelab Co. dba Thrivelab | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Thrivelab’s website, https://www.thrivelab.com, FDA Establishment Identifier (FEI) 3043997633, in March 2026.” | fda.gov |
| tryamie.com | Amie Health, Inc. dba Amie | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Amie Health, Inc.’s website, https://tryamie.com, FDA Establishment Identifier (FEI) 3044000672, in March 2026.” | fda.gov |
| tryeden.com | Eden Health International Inc. dba Eden | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of Eden’s website, https://www.tryeden.com, FDA Establishment Identifier (FEI) 3044020039, in March 2026.” | fda.gov |
| trygenesis.com | Genesis Health International Inc. dba Genesis | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.trygenesis.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| trymeasured.com | Better Health Labs, Inc. dba Measured | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymeasured.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| trymhealth.com | TRYM Health, Inc. dba TRYM Health | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymhealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| trynovamd.com | Try Nova | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trynovamd.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” | fda.gov |
| tuyohealth.com | Tuyo Health, Inc. dba Tuyo Health | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.tuyohealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| usapeptide.com | USApeptide.com | Not stated | Feb 26, 2025 | Unapproved New Drugs/Misbranded The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.usapeptide.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| uschemlabs.com | US Chem Labs | Not stated | Feb 7, 2024 | CGMP/Finished Pharmaceuticals/Adulterated The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.uschemlabs.com in October 2023 and has observed that your website offers “Semaglutide,” “Tirzepatide” and “Thymalin” products for sale in the United States.” | fda.gov |
| villashealth.com | Las Villas Health Care LLC dba Villas Health | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://villashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.” | fda.gov |
| vitalsrx.com | Vitals RX | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://vitalsrx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| viviomd.com | VivioMD Group LLC dba VivioMD | Telehealth | Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “FDA Review Violations were identified and documented during a review of VivioMD’s website, https://viviomd.com, FDA Establishment Identifier (FEI) 3044027316, in March 2026.” | fda.gov |
| vivrx.com | Viv Health, Inc. dba VIV RX | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.vivrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” | fda.gov |
| weightcrunchshop.com | www.weightcrunchshop.com | Online seller | Jan 13, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.weightcrunchshop.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …” | fda.gov |
| xcelpeptides.com | Xcel Research LLC | Not stated | Dec 10, 2024 | Unapproved New Drugs/Misbranded The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://www.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and …” | fda.gov |
| ybycmeds.com | ybycmeds | Telehealth | Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://ybycmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” | fda.gov |
| zappyhealth.com | Kare Solutions, LLC dba Zappy | Telehealth | Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://zappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.” | fda.gov |
Each letter is addressed to the firm in the second column, not to the website. The quoted sentence is the letter’s own reference to the site.
Common questions
Does an FDA warning letter name tryeden.com?
Yes. FDA’s warning letter dated Jun 8, 2026 is addressed to Eden Health International Inc. dba Eden, not to the website. It refers to the site in these words: “FDA Review Violations were identified and documented during a review of Eden’s website, https://www.tryeden.com, FDA Establishment Identifier (FEI) 3044020039, in March 2026.” The FDA subject line is “False & Misleading Claims/Misbranded (Telehealth).”
Does an FDA warning letter name ivimhealth.com?
Yes. FDA’s warning letter dated Feb 20, 2026 is addressed to Ivim Services LLC dba Ivim, not to the website. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.ivimhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” The FDA subject line is “False & Misleading Claims/Misbranded (Telehealth).”
Does an FDA warning letter name hims.com?
Yes. FDA’s warning letter dated Sep 9, 2025 is addressed to Hims & Hers Health, Inc. dba Hims, not to the website. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.hims.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” The FDA subject line is “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth).”
Why are some brands not on this list?
This list covers websites named in FDA warning letters that name a GLP-1 drug. A brand that has not received such a letter does not appear, and this site does not create pages for companies without a public record.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.